1 week Ago By ABMN Staff
Norges Bank purchased a new position in shares of Adicet Bio, Inc. ( NASDAQ:ACET – Free Report ) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 429,550 shares of the company’s stock, valued at approximately $413,000.
Several other hedge funds also recently modified their holdings of ACET. FMR LLC increased its position in Adicet Bio by 31.3% during the third quarter.
FMR LLC now owns 276,169 shares of the company’s stock worth $398,000 after acquiring an additional 65,903 shares during the period. XTX Topco Ltd grew its position in Adicet Bio by 12.5% in the 3rd quarter.
XTX Topco Ltd now owns 292,180 shares of the company’s stock worth $421,000 after purchasing an additional 32,392 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Adicet Bio by 14.5% during the 3rd quarter.
Geode Capital Management LLC now owns 768,566 shares of the company’s stock worth $1,107,000 after purchasing an additional 97,567 shares during the period. JPMorgan Chase & Co. raised its position in shares of Adicet Bio by 10,321.
9% during the third quarter. JPMorgan Chase & Co. now owns 80,353 shares of the company’s stock valued at $116,000 after buying an additional 79,582 shares during the last quarter.
Finally, Regeneron Pharmaceuticals Inc. bought a new stake in shares of Adicet Bio in the fourth quarter valued at about $931,000. 83.
89% of the stock is owned by institutional investors. Adicet Bio Stock Up 20.1 % Shares of ACET opened at $0.
54 on Friday. The company has a 50-day moving average price of $0.82 and a two-hundred day moving average price of $1.
01. The stock has a market cap of $44.40 million, a price-to-earnings ratio of -0.
31 and a beta of 1.99. Adicet Bio, Inc.
has a 12 month low of $0.45 and a 12 month high of $2.35.
Analyst Ratings Changes Several equities analysts recently issued reports on ACET shares. Guggenheim restated a “buy” rating and set a $7.00 price target on shares of Adicet Bio in a research note on Friday, March 21st.
HC Wainwright reissued a “neutral” rating on shares of Adicet Bio in a report on Friday, March 7th. Finally, JMP Securities restated a “market perform” rating on shares of Adicet Bio in a research note on Thursday, February 6th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company’s stock.
According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $7.50. Get Our Latest Research Report on Adicet Bio Adicet Bio Profile ( Free Report ) Adicet Bio, Inc, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer.
The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Featured Articles Want to see what other hedge funds are holding ACET? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Adicet Bio, Inc. ( NASDAQ:ACET – Free Report ). Receive News & Ratings for Adicet Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adicet Bio and related companies with MarketBeat.
com's FREE daily email newsletter ..
